Tag: CAR T cell therapy
-
Immune Complications Drive Higher Infection Risk in Advanced Myeloma Therapies
Overview: A New Frontier in Multiple Myeloma Treatment Chimeric Antigen Receptor (CAR T-cell) therapy and bispecific antibody (BsAb) therapy have transformed the management of advanced multiple myeloma (MM). These immunotherapies mobilize the patient’s own immune system to target and destroy malignant plasma cells, offering durable responses for many who have exhausted conventional therapies. Yet, with…
-
HIV Research: A Catalyst for Breakthroughs Across Medicine
The Enduring Impact of HIV Research HIV/AIDS research has become more than a focused effort against a single disease. Over the past four decades, U.S.-funded HIV research has advanced science in ways that touch immunology, cancer therapy, vaccines, and global health at large. A recent Nature Medicine commentary by leading researchers highlights how this sustained…
-
HIV Research: A Catalyst for Global Medicine and Innovation
Introduction: A Forty-Year Arc of Impact HIV/AIDS research has not only transformed care for people living with HIV but has become a powerful engine of scientific discovery across medicine. In a recent Nature Medicine commentary, leading researchers reflect on four decades of U.S.-funded HIV science and its outsized influence on immunology, cancer therapy, cardiovascular and…
-
Engineered CAR T Cells Target Solid Tumors with IL-12 PD-L1 Fusion
A new approach targets solid tumors Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment landscape for certain blood cancers, but solid tumors—such as prostate, breast, lung, and ovarian cancers—have remained stubborn hurdles. A collaboration between USC Norris Comprehensive Cancer Center and City of Hope has yielded a promising solution: engineering CAR T…